BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 29809305)

  • 1. Down-regulation of CD19 expression inhibits proliferation, adhesion, migration and invasion and promotes apoptosis and the efficacy of chemotherapeutic agents and imatinib in SUP-B15 cells.
    Wu J; Liang B; Qian Y; Tang L; Xing C; Zhuang Q; Shen Z; Jiang S; Yu K; Feng J
    Cell Biol Int; 2018 Sep; 42(9):1228-1239. PubMed ID: 29809305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.
    Shi F; Len Y; Gong Y; Shi R; Yang X; Naren D; Yan T
    PLoS One; 2015; 10(8):e0136746. PubMed ID: 26317515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting miR-21 sensitizes Ph+ ALL Sup-b15 cells to imatinib-induced apoptosis through upregulation of PTEN.
    Wang WZ; Lin XH; Pu QH; Liu MY; Li L; Wu LR; Wu QQ; Mao JW; Zhu JY; Jin XB
    Biochem Biophys Res Commun; 2014 Nov; 454(3):423-8. PubMed ID: 25451263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD9 knockdown suppresses cell proliferation, adhesion, migration and invasion, while promoting apoptosis and the efficacy of chemotherapeutic drugs and imatinib in Ph+ ALL SUP‑B15 cells.
    Xing C; Xu W; Shi Y; Zhou B; Wu D; Liang B; Zhou Y; Gao S; Feng J
    Mol Med Rep; 2020 Oct; 22(4):2791-2800. PubMed ID: 32945456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Niemann-Pick disease type C1(NPC1) is involved in resistance against imatinib in the imatinib-resistant Ph+ acute lymphoblastic leukemia cell line SUP-B15/RI.
    Naren D; Wu J; Gong Y; Yan T; Wang K; Xu W; Yang X; Shi F; Shi R
    Leuk Res; 2016 Mar; 42():59-67. PubMed ID: 26818574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of VE-cadherin on sensitivity to Imatinib in Sup-B15 Philadelphia chromosome positive acute lymphoblastic leukemia cells].
    Zhang HX; Yan ZL; Song XG; Lü C; Cao J; Li ZY; Zeng LY; Chen C; Xu KL
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jun; 34(6):522-6. PubMed ID: 23827112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The Roles of Glut5 in Imatinib Resistance in the Ph
    Yan TY; Naren DL; Gong YP
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2017 May; 48(3):389-393. PubMed ID: 28616912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The study of resistant mechanisms and reversal in an imatinib resistant Ph+ acute lymphoblastic leukemia cell line.
    Xing H; Yang X; Liu T; Lin J; Chen X; Gong Y
    Leuk Res; 2012 Apr; 36(4):509-13. PubMed ID: 22285507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anti-leukemia effect of oridonin on Ph(+) acute lymphoblastic leukemia cell SUP-B15].
    Guo Y; Shan QQ; Gong YP; Lin J; Yang X; Zhou RQ
    Zhonghua Xue Ye Xue Za Zhi; 2012 Jun; 33(6):439-43. PubMed ID: 22967375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway.
    Huang R; Liu H; Chen Y; He Y; Kang Q; Tu S; He Y; Zhou X; Wang L; Yang J; Wu A; Li Y
    Oncol Rep; 2018 Jan; 39(1):119-128. PubMed ID: 29192326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Curcumin potentiates the anti-leukemia effects of imatinib by downregulation of the AKT/mTOR pathway and BCR/ABL gene expression in Ph+ acute lymphoblastic leukemia.
    Guo Y; Li Y; Shan Q; He G; Lin J; Gong Y
    Int J Biochem Cell Biol; 2015 Aug; 65():1-11. PubMed ID: 25979368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Multidrug resistant gene MDR1 contributes to development of imatinib-resistance in Ph (+) acute lymphoblastic leukemia cell line SUP-BS15RI].
    Lin J; Xing HY; Gong YP; Yang X; Guo Y; Shan QQ; Zhou RQ
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Sep; 43(5):657-60, 665. PubMed ID: 23230732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The Mechanism of Combination using mTORC1/2 Inhibitor and Imatinib to Suppress Cell Proliferation of Ph
    Wu JH; Shi FF; Gong YP; Shi R
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2017 Mar; 48(2):216-220. PubMed ID: 28612529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Huaier extract enhances the treatment efficacy of imatinib in Ik6
    Qu P; Han J; Qiu Y; Yu H; Hao J; Jin R; Zhou F
    Biomed Pharmacother; 2019 Sep; 117():109071. PubMed ID: 31202171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of stromal cells on sentitivity to imatinib in Sup-B15 Philadelphia chromosome positive acute lymphoblastic leukemia cells].
    Zhang H; Chen C; Yan Z; Song X; Chen W; Li D; Qiu T; Zhang P; Zeng L; Li Z; Xu K
    Zhonghua Xue Ye Xue Za Zhi; 2015 Jun; 36(6):460-4. PubMed ID: 26134008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway.
    Wei YL; Liang Y; Xu L; Zhao XY
    Anat Rec (Hoboken); 2009 Jul; 292(7):945-50. PubMed ID: 19548306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD-200 induces apoptosis and inhibits Bcr-Abl signaling in imatinib-resistant chronic myeloid leukemia with T315I mutation.
    Fang Z; Jung KH; Yan HH; Kim SJ; Son MK; Rumman M; Lee H; Kim KW; Yoo HD; Hong SS
    Int J Oncol; 2015 Jul; 47(1):253-61. PubMed ID: 25963192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The autophagy induced by curcumin via MEK/ERK pathway plays an early anti-leukemia role in human Philadelphia chromosome-positive acute lymphoblastic leukemia SUP-B15 cells.
    Guo Y; Shan QQ; Gong PY; Wang SC
    J Cancer Res Ther; 2018; 14(Supplement):S125-S131. PubMed ID: 29578162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells.
    Wong SM; Liu FH; Lee YL; Huang HM
    PLoS One; 2016; 11(1):e0148093. PubMed ID: 26815740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation.
    Kim SJ; Jung KH; Yan HH; Son MK; Fang Z; Ryu YL; Lee H; Lim JH; Suh JK; Kim J; Lee S; Hong S; Hong SS
    Oncotarget; 2015 Jan; 6(3):1507-18. PubMed ID: 25483100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.